Michalski Huettermann Patent Attorneys, Duesseldorf, Germany.
MAbs. 2011 May-Jun;3(3):310-7. doi: 10.4161/mabs.3.3.15530. Epub 2011 May 1.
In the last decade, therapeutic antibodies have become one of the commercially most successful classes of biopharmaceutical drugs. Major drug manufacturers who have successfully managed to occupy this new market, as well as biotechnology firms, some of which have experienced a quick growth and are now on par with the former, owe part of their success to suitable intellectual property strategies. This article provides an overview of the current thinking on antibody-related patents, and discusses strategies for protecting the antibody products of the future.
在过去的十年中，治疗性抗体已成为商业上最成功的生物制药药物之一。成功占领这一新兴市场的大型制药商和生物技术公司（其中一些发展迅速，现已与前者并驾齐驱），部分归功于合适的知识产权策略。本文概述了当前关于抗体相关专利的思路，并探讨了保护未来抗体产品的策略。
